Amylin (AMLN) Attracting a Host of Other Suitors, Shares Rise

Article Stock Quotes (6) Comments (0)

Shares of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) are 5 percent higher early Tuesday following reports indicating Bristol-Myers Squibb (NYSE: BMY) is not the only company interested in the diabetes drugs maker.

Amylin has signed confidentiality agreements Pfizer Inc. (NYSE: PFE), AstraZeneca Plc (NYSE: AZN), Sanofi (NYSE: SNY) Merck & Co. (NYSE: MRK), Takeda Pharmaceutical Co., Roche Holding AG, in addition to Bristol-Myers, Bloomberg reported, citing people familiar with the matter.

First-round bids are due in the next two weeks, the report said.

In March, Amylin rejected a $22 per share bid from Bristol-Myers. Since, share have climbed to nearly $27 per share.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Bausch & Lomb near deal to sell to Valeant Pharmaceuticals (VRX) - WSJ
• Tween/Teen Retail Stocks on Watch After rue21 (RUE) Acquired at 23% Premium
• Iconix Brand Group (ICON) Buys Remaining Interest in IP Holdings

Create E-mail Alert Related Categories

Mergers and Acquisitions, Rumors

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?